The short version
10 companies supply this market — deep enough that no single failure threatens the supply.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Fosaprepitant
Fosaprepitant · FOSAPREPITANT DIMEGLUMINE 150 mg/5mL · Injection, Powder, Lyophilized, For Solution · Intravenous · BluePoint Laboratories
NDC 68001-0675-25 · 1 VIAL, SINGLE-DOSE in 1 CARTON / 5 mL in 1 VIAL, SINGLE-DOSE · ANDA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Estimated fill cost
WAC per package, as filed
$82.18
Reported to Texas DSHS · 2026 annual filing · Blue Point Laboratories
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Medicare Part B (ASP)
Payment limit per 1 MG
$0.123
HCPCS J1453 · Jul 1, 2026 quarter · typically ASP + 6%
Medicaid spend (2026 YTD · Q1)ⓘ
$787
52 prescriptions paid by Medicaid nationally · all Medicaid spend →
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Where it's made
- analysis · manufacture
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Is this a "specialty" drug?
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- ANDA209965
- TE code
- AP
- Approval date
- Sep 5, 2019
- Patents / exclusivity
- None on file
Shortage history
- Planned discontinuation — Fosaprepitant Dimeglumine, Injection, 150 mg/5 mL (NDC 63323-972-10)Apr 8, 2026
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Fosaprepitant (Injection, Powder, Lyophilized, For Solution)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Novadoz Pharmaceuticals LLC | FOSAPREPITANT DIMEGLUMINE 150 mg/5mL | Jul 15, 2026 | Sep 3, 2026 |
| Actavis Pharma, Inc. | FOSAPREPITANT DIMEGLUMINE 150 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| BE Pharmaceuticals Inc. | FOSAPREPITANT DIMEGLUMINE 150 mg/5mL | Jul 15, 2026 | Sep 2, 2026 |
| BluePoint Laboratories | FOSAPREPITANT DIMEGLUMINE 150 mg/5mL | Jul 15, 2026 | Sep 2, 2026 |
| Bryant Ranch Prepack | FOSAPREPITANT DIMEGLUMINE 150 mg/5mL | Jul 15, 2026 | Sep 2, 2026 |
| Dr. Reddy's Laboratories Inc., | FOSAPREPITANT DIMEGLUMINE 150 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Fresenius Kabi USA, LLC | FOSAPREPITANT DIMEGLUMINE 150 mg/5mL | Jul 15, 2026 | Sep 2, 2026 |
| Mylan Institutional LLC | FOSAPREPITANT DIMEGLUMINE 150 mg/5mL | Jul 15, 2026 | Sep 2, 2026 |
| Northstar Rx LLC | FOSAPREPITANT DIMEGLUMINE 150 mg/5mL | Jul 15, 2026 | Sep 2, 2026 |
| Dr. Reddy's Laboratories Inc., | FOSAPREPITANT DIMEGLUMINE 150 mg/5mL | Jul 15, 2026 | Aug 31, 2026 |
| AVYXA Pharma, LLC | FOSAPREPITANT DIMEGLUMINE 150 mg/5mL | Jul 31, 2026 | Aug 28, 2026 |
| Avyxa Pharma, LLC | FOSAPREPITANT DIMEGLUMINE 150 mg/5mL | Jul 15, 2026 | Jul 29, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Fosaprepitant — NDC 68001-0675-25," retrieved September 3, 2026, https://drugdashboards.com/drug/68001067525.
Free to cite with attribution — see how the data is put together.